The Emulate Liver-Chip S1 is nearing final FDA qualification as the first organ-on-a-chip drug development tool for predicting drug-induced liver injury. This advancement enables tech professionals to integrate high-throughput microfluidic systems and automated liquid handlers into preclinical workflows, providing human-relevant data that is significantly more accurate than traditional animal models. Success in this final phase will establish a validated regulatory pathway for replacing animal testing with advanced in vitro assays and computational modeling.
Read the full article at Genetic Engineering News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.
0
Ali NematiWritten by Ali
